EFCAB14

Across TCGA pan-cancer cohorts, EFCAB14 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EFCAB14 data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher EFCAB14 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated EFCAB14 expression acts as an unfavorable survival marker.

READ, COAD, and LUAD are the cancer types where EFCAB14 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	DFS	Median	III,IV	0.059	0.761	<.001	36	view →
COAD	OS	Median	III,IV	0.056	0.783	<.001	30	view →
LUAD	OS	Median	All	0.228	0.685	.002	15	view →
SCLC	OS	Median	All	0.219	0.706	.011	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EFCAB14–READ (DFS)

Open the READ breakdown →